ABSTRACT

Multiple myeloma is the second most prevalent hematological malignancy, with over 55,000 new cases diagnosed each year. This exciting new text, edited by lauded authorities on the topic, stands as the only available reference to assemble, review, and synthesizes the latest studies on translational therapies and clearly explains the impact of molecu

chapter 1|22 pages

Xenograft Animal Models for Preclinical Evaluation of Potential Anti-MM Therapeutics: Strengths and Limitations

ByConstantine S. Mitsiades, Kenneth C. Anderson, Daniel R. Carrasco

chapter 2|22 pages

The Role of the Bone Marrow Microenvironment in the Pathogenesis of Multiple Myeloma

ByTeru Hideshima, Noopur Raje

chapter 3|16 pages

Myeloma Bone Disease

ByAlissa Huston, G. David Roodman

chapter 4|14 pages

Niches Within the Multiple Myeloma Bone Marrow Microenvironment

ByKlaus Podar, Irene Ghobrial, Teru Hideshima, Dharminder Chauhan, Kenneth C. Anderson

chapter 5|20 pages

Novel Therapeutic Targets in Multiple Myeloma

ByGiovanni Tonon

chapter 6|20 pages

Monoclonal Gammopathy of Undetermined Significance

ByRobert A. Kyle, S. Vincent Rajkumar

chapter 8|28 pages

Novel Agents for Previously Untreated Multiple Myeloma

BySheeba Thomas, Tiffany Richards, Donna M. Weber

chapter 9|28 pages

Novel Therapeutic Options for the Treatment of Relapsed and Relapsed, Refractory Myeloma

ByMelissa Alsina, Paul Richardson

chapter 10|14 pages

High-Dose Therapy in Multiple Myeloma

ByJean-Luc Harousseau

chapter 11|32 pages

Promising New Agents in Phase I and II Clinical Trials in Multiple Myeloma

ByXavier Leleu, Kenneth C. Anderson

chapter 12|18 pages

Immunotherapeutic Strategies for the Management of Multiple Myeloma

ByRao H. Prabhala, Dheeraj Pelluru, Nikhil C. Munshi

chapter 13|16 pages

Novel Therapeutic Options in Primary Systemic Amyloidosis

ByMorie A. Gertz

chapter 14|22 pages

Novel Options of Therapy in Waldenstro¨m Macroglobulinemia

ByIrene M. Ghobrial, Anne-Sophie Moreau, Xavier Leleu, Meletios A. Dimopoulos